Clinic

The Jakob Herz Prize was awarded for the seventh time on Friday October 7, 2022. The prize is awarded together with the Research Foundation at Universitätsklinikum Erlangen every two years for outstanding scientific achievements from theoretical and clinical medicine. This year’s award winner Prof. Dr. Douglas F. Easton from Cambridge (England), received the Jakob Herz Prize in recognition of his breakthroughs in breast cancer research.

Dr. Adran Regensburger, a doctor in the Department of Pediatrics and Adolescent Medicine, has received the ‘Young Investigator Award’ for his work in molecular imaging in children with muscular dystrophy. The jury particularly praised the innovatory value and method selected by Dr. Regensburger.

In 2012, UK Erlangen was the first hospital in Middle Franconia to use a robot-assisted surgical system. The hospital has now invested over 2.4 million euros in a new da Vinci Xi to enable it to increase the precision of surgical procedures in the future with the latest generation of the robot-assisted surgical system.

An important step on the path towards creating an artificial ovary for patients suffering from cancer: Scientists at FAU are researching innovative techniques for restoring fertility in cancer patients.

Die vermehrte Ablagerung von Bindegewebe ist ein Problem bei chronischen Erkrankungen vieler Organe. Effektive Behandlungsmöglichkeiten stehen derzeit kaum zur Verfügung. Wissenschaftler aus der Medizinischen Klinik 3 haben jetzt ein molekulares Netzwerk entschlüsselt, das diese Prozesse kontrolliert und dadurch eine neue Möglichkeit für die Therapie von Organvernarbung darstellen könnte.

There is a strong link between depression and anxiety disorders and autoimmune thyroiditis (AIT), a chronic thyroid disease affecting approximately 10 percent of the population. Special treatment could help a lot of sufferers – especially women.

The Department of Medicine 4 is a member of a worldwide consortium that has the aim of improving treatment of chronic kidney disease.

Researchers at the Department of Neurology demonstrated the significant influence of new signal paths of the renin-angiotensin system (RAS).

The patient perspective is important in all medical research, and particularly in drug development. This is reflected in the European research initiative PREFER in which a research group at the Department of Medicine 3 is involved.

A study shows a new, surprising role played by blood vessels: under certain conditions they can inhibit tumor growth.